AMGEN INC (AMGN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for AMGN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| AMGN | Director | 70 | ["President of Oregon Health & Science University","Physician-scientist","Professor of medicine","JELD-WEN chair of leukemia research","Former associate dean for oncology of the OHSU School of Medicine","Former investigator with the Howard Hughes Medical Institute","Former director of Vincerx Pharma, Inc.","Member of the scientific advisory board of Aptose Biosciences Inc.","Founder of Blueprint Medicines Corporation","Founder of MolecularMD","Member of the board of directors of the Burroughs Wellcome Fund","Lasker-DeBakey Clinical Research Award recipient","Japan Prize in Healthcare and Medical Technology recipient","Albany Medical Center Prize recipient","Sjöberg Prize recipient","Elected to the National Academy of Sciences","Elected to the National Academy of Medicine","Undergraduate degree and medical doctorate from University of California, San Diego"] | ["Compensation and Management Development","M","Corporate Responsibility and Compliance","Corporate Responsibility and Compliance Committee"] | 2026 |
Biography sourced from the proxy statement filing.
the scientific advisory board of Aptose Biosciences Inc., a biotechnology company, since 2013. Dr. Druker has been a consultant to GRAIL, Inc. (formerly known as GRAIL, LLC), a biotechnology company, since 2021, and served on its scientific advisory board, from 2016 to 2019. In 2011, he founded Blueprint Medicines Corporation, a biopharmaceutical company, and served as a scientific advisor to this company until its acquisition by Sanofi S.A. in July 2025. In 2006, he founded MolecularMD, a privately held molecular diagnostics company that was acquired by ICON plc in 2019. Dr. Druker has been a member of the board of directors of the Burroughs Wellcome Fund since 2018, an independent, private foundation supporting research and other scientific and education activities. Dr. Druker has received numerous awards, including the Lasker-DeBakey Clinical Research Award in 2009, the Japan Prize in Healthcare and Medical Technology in 2012, the Albany Medical Center Prize in 2013, and the Sj berg Prize in 2019, for influential work in the development of STI571 (Gleevec ) for the treatment of chronic myeloid leukemia. He was elected to the National Academy of Sciences in 2012 as well as the National Academy of Medicine in 2007. Dr. Druker received both an undergraduate degree and his medical doctorate from the University of California, San Diego. Qualifications Our Board concluded that Dr. Druker should serve on our Board based on his extensive scientific research and expertise leading an important academic institution, conducting highly significant research in the area of oncology, and directly managing the care of cancer patients.